# Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)

> **NCT03888534** · PHASE1 · WITHDRAWN · sponsor: **Millennium Pharmaceuticals, Inc.**

## Conditions studied

- Precursor Cell Lymphoblastic Leukemia-lymphoma

## Interventions

- **DRUG:** Ixazomib

## Key facts

- **NCT ID:** NCT03888534
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10-31
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision (no safety or efficacy concerns)
- **Last updated:** 2020-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03888534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03888534, "Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03888534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*